Clinical trial
Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)
NCT00479388 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00479388 |
|---|---|
| Title | Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067) |
| Official title | A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of Extended-release (ER) Niacin/Laropiprant in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia. |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Primary Hypercholesterolemia, Mixed Dyslipidemia |
| Intervention type | Drug |
| Interventions | Comparator: simvastatin, niacin (+) laropiprant, Comparator: atorvastatin calcium |
| Enrollment | 1,216 |
| Start date | Jul 1, 2007 |
| Primary completion | Jul 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | May 28, 2007 |
| Last update posted | Mar 10, 2015 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: